KEYMAKER-U02- substudy 02B
Enrolling By Invitation
18-99 years
All
Phase
1
15 participants needed
1 Location
Brief description of study
Patients from Penn Medicine's Abramson Cancer Center will be approached for participation.
This sub-study is part of a larger
research study that is testing experimental treatments for melanoma.
Various study drugs will be tested in combination with pembrolizumab in
this study. Treatment groups include: a) MK-7684 and pembrolizumab b)
pembrolizumab alone c) MK-1308A and d) MK-1308A and lenvatinib.
Eligible subjects will be those with melanoma.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: melanoma
-
Age: Between 18 Years - 99 Years
-
Gender: All
Updated on
01 Aug 2024.
Study ID: 848898
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
